Evaluating the efficacy and safety of Anlotinib in conjunction with stereotactic radiosurgery for small cell lung cancer patients with brain metastases.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is characterized by its aggressive nature and high propensity for brain metastases. This study investigates the clinical efficacy and safety profile of Anlotinib in combination with Stereotactic Radiotherapy (SRT) for treating brain metastases in patients with small cell lung cancer (SCLC).

Methods

This research included 98 SCLC brain metastasis patients treated at Chengde Central Hospital from October 2020 to January 2024. The patients were categorized into a combined treatment group (CTG) (n = 45) and a Simple SRT group (SSG)(n = 53). The CTG (58 lesions) received Anlotinib with brain SRS, while the SSG (67 lesions) underwent only brain SRS. We compared the rates of intracranial hypertension relief, intracranial lesion treatment eff

SUBMITTER: Wang L 

PROVIDER: S-EPMC11964871 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature